Despite high profile events such as the industry's showcase BIO 2006 in April and the annual meeting of the American Society of Clinical Oncology (ASCO) in June, they failed to generate any "buzz" for biotech investors in the second quarter. "For a number of reasons investor confidence in biotech
is at a low ebb," said G. Steven Burrill, CEO of Burrill & Company a
San Francisco based global leader in life sciences whose principal activities
are in Venture Capital, Merchant Banking and Media.
dBusinessNews.com
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Paige Earns CE Mark for Prostate Cancer Detection Solution
“Pathology practices around the world have begun to embrace digital pathology,” said Paige CEO Leo Grady.
Ranitidine Tests Find NDMA Levels Akin to Levels in Food, Woodcock Says
The agency asked manufacturers to voluntarily recall another H2 blocker nizatidine, or Axid, if they find NDMA above the acceptable daily intake level.
FDAnews Drug Daily Bulletin
BIOTECH ON A DOWNWARD SLIDE IN Q2 06
July 6, 2006
